Pfizer and Hikma will manufacture ramdevpir

British Hikma announced the start of production of ramdevpir of Gilead, which is currently used for the treatment of patients with COVID-19. A similar agreement for the production of antiretroviral drug Gilead has entered into with Pfizer, writes Reuters.

Ramdevpir is one of two drugs that have confirmed efficacy in the treatment of coronavirus infection in hospitalized patients. Worldwide there is high demand for ramdevpir, forcing Gilead to seek partners for the production of a drug.

In the framework of the agreement, Hikma will adjust the release of ramdevpir in Portugal. As for Pfizer, it intends to make an antiretroviral drug at its plant in Kansas. Financial terms of both deals were not disclosed.

Leave a Reply

Your email address will not be published. Required fields are marked *

Releated

For the six months Kurgan “Synthesis” increased revenue by 42%

Revenue of JSC “Sintez” (part of the Allium Group) for 6 months of 2020 has increased by 42% year-on-year to 6,767 billion. Net profit reached 752.9 million roubles that on 23% more than in the same period last year. Export sales grew by 36% year-on-year, exceeding 1 billion rubles, told in the company. Secondary sales […]

Russia confirmed on 5 065 new cases COVID-19

In recent days in Russia identified 5 065 new cases of coronavirus in 83 regions. Died 114 people, fully recovered 6 568 patients. In Moscow confirmed 688 new cases of coronavirus. The average rate of increase of new cases for the first two weeks of August is 0.28%. This figure compares with the first two […]